Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPXNASDAQ:HUMANASDAQ:ITOSNYSE:RCOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$1.90-2.1%$2.20$0.77▼$4.08$262.74M1.4876,323 shs553,490 shsHUMAHumacyte$1.46+1.4%$2.32$1.15▼$9.97$226.47M1.623.58 million shs1.33 million shsITOSiTeos Therapeutics$7.07-3.8%$6.58$4.80▼$18.75$205.87M1.43479,948 shs419,801 shsRCORRenovacor$3.20$3.07$1.34▼$9.74$55.26M-0.2830,033 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics0.00%+10.86%-2.51%-31.21%+33.79%HUMAHumacyte0.00%-14.29%-26.53%-68.07%-63.91%ITOSiTeos Therapeutics0.00%+12.90%+16.30%-2.39%-31.94%RCORRenovacor0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPXCompass Therapeutics3.3595 of 5 stars4.61.00.00.02.55.00.0HUMAHumacyte2.6456 of 5 stars3.52.00.00.02.23.30.6ITOSiTeos Therapeutics2.4352 of 5 stars3.51.00.00.03.22.50.6RCORRenovacorN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 3.11Buy$13.38603.95% UpsideHUMAHumacyte 3.00Buy$13.71839.33% UpsideITOSiTeos Therapeutics 3.00Buy$25.75264.21% UpsideRCORRenovacor 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RCOR, ITOS, CMPX, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.004/2/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025CMPXCompass TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.004/1/2025CMPXCompass TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/1/2025CMPXCompass TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.004/1/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K309.10N/AN/A$1.17 per share1.62HUMAHumacyte$1.57M144.25N/AN/A$0.13 per share11.23ITOSiTeos Therapeutics$35M7.72N/AN/A$16.08 per share0.44RCORRenovacorN/AN/AN/AN/A$2.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$42.49M-$0.37N/AN/AN/AN/A-32.37%-30.67%5/12/2025 (Estimated)HUMAHumacyte-$110.78M-$1.26N/AN/AN/AN/A-942.81%-93.82%5/9/2025 (Estimated)ITOSiTeos Therapeutics-$112.64M-$3.31N/AN/AN/AN/A-20.11%-17.50%5/9/2025 (Estimated)RCORRenovacor-$14.10M-$0.73N/AN/AN/AN/A-62.88%-48.90%N/ALatest RCOR, ITOS, CMPX, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CMPXCompass Therapeutics-$0.12N/AN/AN/AN/AN/A5/9/2025Q1 2025HUMAHumacyte-$0.19N/AN/AN/A$0.46 millionN/A5/9/2025Q1 2025ITOSiTeos Therapeutics-$0.94N/AN/AN/A$1.80 millionN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/A2/27/2025Q4 2024CMPXCompass Therapeutics-$0.10-$0.11-$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ARCORRenovacorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A31.8431.84HUMAHumacyteN/A1.101.10ITOSiTeos TherapeuticsN/A14.8014.80RCORRenovacorN/A6.606.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%HUMAHumacyte44.71%ITOSiTeos Therapeutics97.16%RCORRenovacor45.84%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics28.50%HUMAHumacyte11.20%ITOSiTeos Therapeutics12.50%RCORRenovacor14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20138.28 million98.38 millionNot OptionableHUMAHumacyte150155.12 million111.76 millionOptionableITOSiTeos Therapeutics9038.19 million31.97 millionOptionableRCORRenovacor1917.27 million14.78 millionNot OptionableRCOR, ITOS, CMPX, and HUMA HeadlinesRecent News About These CompaniesBest budget record players 2024: affordable turntables tried and testedNovember 6, 2024 | whathifi.comThe Lititz Record-ExpressOctober 25, 2024 | lancasteronline.comWNBA Delivers Record-Setting 2024 SeasonOctober 13, 2024 | wnba.comRBC Core Bond Pool ETF (RCOR)July 27, 2024 | investing.comRecord Store Day 2024: How to Flatten Warped Vinyl Records at HomeApril 22, 2024 | cnet.comThe best record players 2024: Top turntables for any budgetApril 20, 2024 | tomsguide.comBest turntables 2024: Bluetooth record players for Record Store DayApril 20, 2024 | stuff.tvNews of RecordMarch 30, 2024 | newsandsentinel.comNHL opening night delivers record viewership on ESPNNovember 6, 2023 | nhl.comState Pension payments worth over £2,000 each month for older people living in these European countriesOctober 30, 2023 | dailyrecord.co.ukThe best early Black Friday turntable deals 2023October 29, 2023 | whathifi.comAnas Sarwar 'unhappy' with Keir Starmer over Labour leader's response to Gaza crisisOctober 27, 2023 | dailyrecord.co.ukNYC shoplifting hit record highs last year: ‘We can’t stop them’October 24, 2023 | nypost.comTranscriptional control of the inflammatory responseOctober 18, 2023 | nature.comRockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of DirectorsOctober 17, 2023 | finance.yahoo.comFolwell criticizes fellow Republicans on public records rollbackOctober 14, 2023 | wral.comBest Bluetooth turntables 2023: wireless record players for streaming vinylOctober 11, 2023 | whathifi.comHere’s why you shouldn’t record meltdowns on an airplane: FAA insiderOctober 3, 2023 | nypost.comRecord-breaking heat wave peaking in Eastern U.S. with highs near 100September 28, 2023 | washingtonpost.comiOS 17: How to Record a FaceTime Video or Audio MessageSeptember 15, 2023 | macrumors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?5 Highly Rated Dividends With 50% Upside According to AnalystsBy Thomas Hughes | April 14, 2025View 5 Highly Rated Dividends With 50% Upside According to AnalystsJ.B. Hunt Transport Overcorrects Into a Buying OpportunityBy Thomas Hughes | April 19, 2025View J.B. Hunt Transport Overcorrects Into a Buying OpportunityMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesRCOR, ITOS, CMPX, and HUMA Company DescriptionsCompass Therapeutics NASDAQ:CMPX$1.90 -0.04 (-2.06%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.79%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Humacyte NASDAQ:HUMA$1.46 +0.02 (+1.39%) Closing price 04:00 PM EasternExtended Trading$1.46 0.00 (-0.34%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.iTeos Therapeutics NASDAQ:ITOS$7.07 -0.28 (-3.81%) Closing price 04:00 PM EasternExtended Trading$7.19 +0.12 (+1.70%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Renovacor NYSE:RCORRenovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
